
Herantis Pharma Investor Relations Material
Latest events

R&D Day 2024
Herantis Pharma
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from Herantis Pharma
Access all reports
Herantis Pharma Oyj is a Finnish biotechnology company focused on developing disease-modifying therapies for neurodegenerative diseases, particularly Parkinson's disease. The company's lead program centers around HER-096, a small synthetic chemical designed to mimic the activity of cerebral dopamine neurotrophic factor (CDNF). This treatment aims to address the progression of Parkinson's by protecting neurons and enhancing their function. The company is headquartered in Espoo, Finland, and its shares are listed on the Helsinki Stock Exchange.
Latest articles
)
Robert G. Hagstrom: Darwinian Investing and Multidisciplinary Wisdom
Robert G. Hagstrom, author of The Warren Buffett Way, explores how interdisciplinary thinking shapes his investing, from Adler's reading to Darwinian markets.
7 Feb 2025
)
Quartr Brings Stories Behind the Numbers to Light
Quartr simplifies access to IR material and puts qualitative insights and company narratives front and center.
3 Feb 2025
)
The Evolution of the IRO Role: Staying Informed and Strategic With Quartr Pro
Staying informed is critical for IROs. Quartr Pro simplifies gathering market insights and narrative positioning with unprecedented speed and precision.
3 Feb 2025
Ticker symbol
HRNTS
Country
🇫🇮 Finland